Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1666 to 1680 of 8899 results

  1. Fostemsavir for treating adults with multidrug resistant HIV-1 for whom it is not possible to construct a suppressive anti-viral regimen [ID2726]

    Awaiting development Reference number: GID-TA10605 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Obeticholic acid for treating liver fibrosis in people with steatohepatitis [ID1645]

    In development Reference number: GID-TA10606 Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Ibalizumab for treating adults infected with multidrug resistant HIV-1 for whom it is not possible to construct a suppressive anti-viral regimen [ID2720]

    Awaiting development Reference number: GID-TA10657 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Sotagliflozin for treating type 2 diabetes [ID1657]

    Awaiting development Reference number: GID-TA10665 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Baloxavir marboxil for treating influenza in people at high risk of complications [ID3794]

    Awaiting development Reference number: GID-TA10683 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Baloxavir marboxil for influenza prophylaxis in people aged 12 and over [ID3793]

    Awaiting development Reference number: GID-TA10684 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Rivoceranib for treating unresectable or advanced gastric or gastro-oesophageal junction cancer after 2 or more therapies [ID3819]

    Awaiting development Reference number: GID-TA10685 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Zanubrutinib for untreated chronic lymphocytic leukaemia [ID5079]

    In development Reference number: GID-TA10966 Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Oxybutynin hydrochloride for managing neurogenic detrusor overactivity in people 6 years and over with spinal cord injury or spina bifida [ID5089]

    In development Reference number: GID-TA10998 Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Odevixibat for treating cholestasis and pruritus in Alagille Syndrome [ID6181]

    In development Reference number: GID-TA11154 Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Selpercatinib for untreated RET-positive advanced thyroid cancer [ID6183]

    In development Reference number: GID-TA11160 Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Renal cell carcinoma Pathways Pilot [ID6186]

    In development Reference number: GID-TA11186 Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Dusquetide for treating oral mucositis during chemoradiation for head and neck cancer [ID3830]

    Awaiting development Reference number: GID-TA10715 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Bupivacaine–meloxicam for treating postoperative pain [ID2728]

    Awaiting development Reference number: GID-TA10716 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Etrolizumab for treating moderately to severely active ulcerative colitis [ID3827]

    Awaiting development Reference number: GID-TA10717 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development